1. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma
- Author
-
Lionel Karlin, Arnaud Jaccard, Margaret Macro, Cyrille Touzeau, Jean-Henri Bourhis, Arthur Bobin, Nabih Azar, Xavier Leleu, Denis Caillot, Guillemette Fouquet, Claire Darras, Laurent Garderet, Thomas Systchenko, Erik Deconinck, Samuel Limat, Cécile Gruchet, Philippe Moreau, Pascal Lenain, Isabelle Princet, Zoé Van de Wyngaert, Virginie Nerich, Christine Giraud, Marie-Lorraine Chretien, Cyrille Hulin, Ramdane Belhocine, Niels Moya, and Stéphanie Guidez
- Subjects
Oncology ,Transplantation ,medicine.medical_specialty ,Mobilization ,Cyclophosphamide ,Stem cell mobilization ,business.industry ,Plerixafor ,Hematology ,medicine.disease ,Hematopoietic Stem Cell Mobilization ,Peripheral ,Apheresis ,Heterocyclic Compounds ,Internal medicine ,Granulocyte Colony-Stimulating Factor ,Peripheral Blood Stem Cells ,medicine ,Humans ,Multiple Myeloma ,Complication ,business ,Multiple myeloma ,medicine.drug - Abstract
Mobilization of peripheral blood stem cells (PBSC) can be performed using plerixafor, which is expensive, or high-dose cyclophosphamide (HDCy). We hypothesized that the overall cost of mobilization with plerixafor might not be greater if the cost of complication management was considered. We performed a cost analysis of these two strategies. This multicentric observational study recruited patients with myeloma who underwent a first PBSC mobilization. We considered direct medical costs, including hospitalization, mobilization agents, apheresis, and supportive treatments. We included 111 patients, 54 and 57 in the HDCy and plerixafor groups, respectively. Cost of mobilization with HDCy was 5097 ± 2982€ vs. 10958 ± 1789€ for plerixafor (p
- Published
- 2020
- Full Text
- View/download PDF